Study Links Chemotherapy Drug to Hearing Loss in Cancer Survivors

A recent study conducted by researchers from the University of South Florida (USF) and Indiana University has revealed that the chemotherapy drug cisplatin may lead to significant hearing loss among testicular cancer survivors. The study tracked 100 survivors who had undergone treatment with cisplatin for an average of 14 years. Lead author Victoria Sanchez emphasized the high risk of permanent hearing loss associated with cisplatin, noting that for some patients, this loss can worsen years after treatment. The research highlights an unexpected correlation between cardiovascular conditions and increased hearing loss, suggesting that lifestyle choices may play a role in protecting hearing health. Sanchez pointed out that the inner ear is particularly susceptible to cisplatin, as it cannot filter out the drug effectively. Cisplatin has been an FDA-approved treatment for testicular cancer since 1978, and its packaging warns of potential ototoxicity, which refers to drug-induced damage to the inner ear. Experts stress the importance of monitoring hearing health for those who have received cisplatin treatment. Sanchez advises patients to seek hearing assessments if they have concerns, as there are treatment options available for hearing loss. While the study's findings are significant, it is noted that the patient group was homogenous, consisting solely of males treated for testicular cancer, which may limit the broader applicability of the results. Overall, the study underscores the need for ongoing awareness and management of hearing health in cancer survivors, particularly those treated with high doses of platinum-based chemotherapy.